Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Actinogen Medical ( (AU:ACW) ).
Actinogen Medical announced its financial results for the year ending June 30, 2025, alongside updates on its clinical trials for Xanamem, a promising therapy for Alzheimer’s Disease and Depression. The company is conducting a Phase 2b/3 trial for Alzheimer’s and a Phase 2a trial for depression, with significant progress reported, including clinically significant benefits on depression symptoms. These developments could enhance Actinogen’s position in the biotechnology industry, offering potential new treatments for debilitating cognitive and neuropsychiatric conditions.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their primary product, Xanamem, is being developed as a treatment for Alzheimer’s Disease, Depression, and potentially other conditions like Fragile X Syndrome, addressing a significant unmet medical need for improved treatments in these areas.
YTD Price Performance: 20.0%
Average Trading Volume: 3,778,263
Technical Sentiment Signal: Hold
Current Market Cap: A$95.31M
Learn more about ACW stock on TipRanks’ Stock Analysis page.